LAURUSLABS - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.7
| Stock Code | LAURUSLABS | Market Cap | 52,914 Cr. | Current Price | 980 ₹ | High / Low | 1,141 ₹ |
| Stock P/E | 66.1 | Book Value | 91.1 ₹ | Dividend Yield | 0.12 % | ROCE | 9.47 % |
| ROE | 7.75 % | Face Value | 2.00 ₹ | DMA 50 | 1,017 ₹ | DMA 200 | 879 ₹ |
| Chg in FII Hold | 0.35 % | Chg in DII Hold | 0.70 % | PAT Qtr | 175 Cr. | PAT Prev Qtr | 216 Cr. |
| RSI | 41.0 | MACD | -26.0 | Volume | 19,65,321 | Avg Vol 1Wk | 19,78,167 |
| Low price | 512 ₹ | High price | 1,141 ₹ | PEG Ratio | -2.85 | Debt to equity | 0.37 |
| 52w Index | 74.4 % | Qtr Profit Var | 206 % | EPS | 14.8 ₹ | Industry PE | 29.2 |
📊 Analysis: Laurus Labs is trading at 980 ₹, below its 50 DMA (1,017 ₹) but above the 200 DMA (879 ₹). This indicates short-term weakness but long-term support. RSI at 41 suggests mildly oversold conditions, while MACD (-26) confirms bearish momentum. Volumes are steady, close to weekly average, showing balanced participation but no strong breakout signal.
💰 Optimal Buy Price (Intraday): 970–975 ₹ (near support zone).
📈 Profit-Taking Levels: 995 ₹ (first resistance), 1,010 ₹ (secondary resistance).
⚠️ Stop-Loss / Loss Protection: 960 ₹ (below intraday support).
⏱️ If Already Holding: Exit if price fails to cross 995 ₹ with volume confirmation or if RSI dips below 38 intraday. Hold for extended gains only if momentum sustains above 1,000 ₹ with strong volume.
Positive
- 📈 Strong quarterly profit variation (206%).
- 📊 Above 200 DMA, showing long-term strength.
- 📉 Debt-to-equity at 0.37, manageable leverage.
- 📈 Institutional accumulation (FII +0.35%, DII +0.70%).
Limitation
- ⚠️ High P/E (66.1) vs industry average (29.2).
- 📉 Weak ROE (7.75%) and ROCE (9.47%).
- 📊 RSI and MACD indicate bearish short-term momentum.
Company Negative News
- 📉 Sequential decline in PAT (216 Cr. → 175 Cr.).
- ⚠️ EPS (14.8 ₹) not aligned with high valuation multiples.
Company Positive News
- 📈 Strong YoY profit growth (206% variation).
- 📊 Consistent institutional buying interest.
Industry
- 🏭 Pharma sector PE at 29.2, Laurus Labs trades at a premium.
- 📈 Defensive sector rotation favors pharma in volatile markets.
Conclusion
⚖️ Laurus Labs is a moderate intraday candidate. Buy near 970–975 ₹ with stop-loss at 960 ₹. Profit booking can be considered at 995–1,010 ₹. Momentum indicators suggest caution, but long-term support remains intact above 200 DMA. Intraday traders should rely on volume confirmation before holding beyond 1,000 ₹.
Would you like me to extend this into a workflow-ready HTML template with peer benchmarking overlays (e.g., Divi’s, Aurobindo, Sun Pharma) so you can directly compare intraday strength across pharma stocks?